To confirm persisting NPM-p53 interaction observed in Selinexor-treated cells transfected with the exogenous FP-labeled proteins, we performed similar experiments with our panel of AML-related cell lines, Figure 11B. Due to the higher sensitivity of AML cells to the treatment, the concentration of Selinexor was lowered eight-fold to 0.5 μM and the exposure of cells to the drug was prolonged from 2 h to 24 h. The gene discussed is TP53; the disease is acute myeloid leukemia.